Massachusetts Financial Services Co. MA Invests $952,000 in GRAIL, Inc. $GRAL

Massachusetts Financial Services Co. MA bought a new position in GRAIL, Inc. (NASDAQ:GRAL) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,943 shares of the company’s stock, valued at approximately $952,000.

Several other hedge funds and other institutional investors also recently modified their holdings of GRAL. Farallon Capital Management LLC raised its stake in shares of GRAIL by 73.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the period. Baker BROS. Advisors LP grew its holdings in GRAIL by 27.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares in the last quarter. Vanguard Group Inc. increased its position in shares of GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after buying an additional 163,790 shares during the period. State Street Corp lifted its holdings in shares of GRAIL by 38.8% in the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of GRAIL by 63.8% in the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after buying an additional 588,647 shares in the last quarter.

Insider Activity at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the transaction, the insider directly owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

GRAL has been the topic of a number of analyst reports. The Goldman Sachs Group began coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 target price on the stock. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Mizuho lifted their price objective on GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Finally, Wolfe Research assumed coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $67.78.

GRAIL Stock Down 0.5%

Shares of NASDAQ GRAL opened at $67.87 on Friday. The firm’s fifty day moving average is $67.58 and its 200 day moving average is $65.35. GRAIL, Inc. has a 52 week low of $29.95 and a 52 week high of $118.84. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -6.96 and a beta of 3.24.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The business had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. Equities research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.